XClose

The Comprehensive Clinical Trials Unit at UCL

Home
Menu

KERALINK

1 November 2018

A Phase II Clinical Trial to establish Efficacy and Safety of cross-linking in children with Keratoconus

The National Institute of Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) Programme is funding research on keratoconus patients to establish the safety and efficacy of crosslinking procedure in children aged 10 - 16 years. Keratoconus is characterised by thinning and distortion of the cornea that results in visual loss from complex refractive error and corneal opacification. The prevalence in Europe is rising with an estimated 50,000 affected individuals in the UK. Keratoconus is often more advanced if it is first diagnosed in childhood, rather than in adults, with faster subsequent disease progression.

Current treatments involve provision of glasses. If spectacle corrected visual acuity is poor, contact lens are provided and visual acuity is reviewed every 6 months. Those patients with advanced disease and poor spectacle and lens corrected visual acuity are offered corneal transplantation. The proposed cross linking procedure is conceived to increase the stiffness of the cornea and stop progression of keratoconus.

This phase II multi-centre; observer masked, randomised controlled trial comparing cross-liking treatment with standard care is carried out in 60 patients to investigate efficacy and safety of epithelium-off cross-linking in the paediatric age group.

Recruitment has now concluded and the trial is now in its follow-up stage.

ISRCTN: 17303768

Publications